RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

American Journal of Pathology

Volumn 162, Issue 4, 2003, Pages 1123-1137

  Wendt, Thoralf M ^a   Tanji, Nozomu ^a   Guo, Jiancheng ^a   Kislinger, Thomas R ^a   Qu, Wu ^a   Lu, Yan ^a   Bucciarelli, Loredana G ^a   Ling Rong, Ling ^a   Moser, Bernhard ^a   Markowitz, Glen S ^a   Stein, Gunther ^b   Bierhaus, Angelika ^c   Liliensiek, Birgit ^d   Arnold, Bernd ^d   Nawroth, Peter P ^c   Stern, David M ^a   D'Agati, Vivette D ^a   Schmidt, Ann Marie ^a  

^a Columbia University ^*  (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; CALGRANULIN; PROTEIN RAGE; PROTEIN S 100; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; INFLAMMATORY CELL; MALE; MESANGIUM; MONONUCLEAR CELL; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOCYTE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA;

EID: 0037377697     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63909-0     Document Type: Article

References (63)

1. Ritz E, Rychilik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimension. Am J Kidney Dis 1999, 34:795-808
2. Koch M, Kutkuhn B, Grabensee B, Ritz E: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialyzed diabetic subjects: prospective study of 412 subjects. Nephrol Dial Transplant 1997, 12:2603-2611
3. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993, 90:1814-1818
4. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 1994, 331:1286-1292
5. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RA: Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 1999, 56:860-872
6. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in stz-induced diabetic mice. Diabetes 1996, 45:522-530
7. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000, 97:8015-8020
8. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48:2229-2239
9. De Vriese A, Tilton R, Vanholder R: Hyperfiltration and albuminuria in diabetes: role of vascular endothelial growth factor (VEGF). J Am Soc Nephrol 1999, 10:A3434 (Abstract)
10. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D: Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration, J Exp Med 1990, 172:1535-1545
11. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migration of monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343
12. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, Bariety J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000, 49:466-475
13. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J; Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000, 57:167-182
14. Furata T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K: The role of macrophages in diabetes glomerulosclerosis. Am J Kidney Dis 1993, 21:180-185
15. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: The expression of advanced glycation endproducts and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. J Am Soc Nephrol 2000, 11:1656-1666
16. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan YC, Tsang TC, Stern D: Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992, 267:14987-14997
17. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston KD, Stern D, Shaw A: Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267:14998-15004
18. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Morser JD, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901
19. Regoli M, Bendayan M: Alterations in the expression of alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 1997, 40:15-22
20. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TM: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348
21. Williams B: A potential role for angiotensin 11-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner Electrolyte Metab 1998, 24:400-404
22. Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 4 1999, 2:1341-1344
23. Phillips A, Janssen U, Floege J: Progression of diabetic nephropathy: insights from cell culture studies and animal models. Kidney Blood Press Res 1999, 22:81-97
24. Pavenstadt H: Roles of the podocyte in glomerular function Am J Physiol 2000, 278:F173-F179
25. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H: Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001, 50:1193-1196
26. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanable T, Nomoto K, Nagata M: Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 2002, 82:25-35
27. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001, 44:878-882
28. Cohen MP, Clements RS, Hud E, Cohen JA, Ziyadeh FN: Evolution of renal functional abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol 1996, 4:166-171
29. Cohen MP, Clements RS, Cohen JA, Shearman CW: Prevention of the decline in renal function in the diabetic db/db mouse. Diabetologia 1996, 39:270-274
30. Sakaguchi T, Sousa M, Yan SD, Yan SF, Duda S, Arnold B, Nawroth PP, Schmidt AM, Stern DM, Naka Y: Restenosis: central role of RAGE-dependent neointimal expansion. Circulation (Suppl) 2001, 104:2471, 11-522
31. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997, 236:248-258
32. Mundel P, Reiser J, Kriz W: Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997, 8:699-705
33. Park L, Raman KG, Lee KJ, Lu Y, Ferran Jr LJ, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE). Nat Med 1998, 4:1025-1031
34. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM: Blockade of RAGE suppresses periodontitis-associated alveolar bone loss in diabetic mice. J Clin Invest 2000, 105:1117-1124
35. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: N ε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995, 34:10872-10878
36. Schleicher ED, Wagner E, Nerlich AG: Increased accumulation of the glycoxidation product N(ε)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997, 99:457-468
37. ε (carboxymethyl) lysine modifications of proteins are ligands for RAGE that activate cell signalling pathways and modulate gene expression. J Biol Chem 1999, 274:31740-31749
38. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, Strihou CY, Monnier VM, Witztum JL, Kurokawa K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions: implication for glycoxidative stress in the pathogenesis of diabetic nephropathy J Clin Invest 1997, 100:2995-3004
39. Schafer BW, Heinzmann CW: The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996, 21:134-140
40. Zimmer DB, Cornwall EH, Landar A, Song W: The S100 protein family: history, function, and expression. Brain Res Bull 1995, 37:417-429
41. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1): a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995, 96:1395-1403
42. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H: Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997, 272:8723-8730
43. Stitt AW, Bhadur T, McMullen CB, Gardiner TA, Archer DB: Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 2000, 3:380-388
44. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T: Suppression of transforming growth factor β and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation endproduct inhibitor, OPB-9195. Diabetologia 1999, 42:579-588
45. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP: Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998, 101: 1219-1224
46. Rovin BH, Schreiner GF: Cell-mediated immunity in glomerular disease Annu Rev Med 1991, 42:25-33
47. Nathan CF: Secretory products of macrophages. J Clin Invest 1987, 79:319-326
48. Iglesias-De La Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S: Effects of high glucose and TGF-β1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002, 62:901-913
49. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456
50. Abbate M, Zoja C, Corna D, Capitano M, Bertani T, Remuzzi G: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998, 9:1213-1224
51. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997, 8:1537-1545
52. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κ B activation. Kidney Int 1998, 53:1608-1615
53. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME: AGEs cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation endproducts (RAGE). J Clin Invest 2001, 108:1853-1863
54. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001, 108:261-268
55. The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT) Study Group. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic subjects with albuminuria Diabetes 2001, 50:843-850
56. Viberti GC, Jarrett RJ, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982, 1:1430-1432
57. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310: 356-360
58. 558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 1993, 90:3645-3649
59. Lotan D, Kaplan BS, Fong JS, Goodyer PR, de Chadarevian JP: Reduction of protein excretion by dimethyl sulfoxide in rats with passive Heymann nephritis. Kidney Int 1984, 25:778-788
60. Kaplan BS, Milner LS, Lotan D, Mills M, Goodyer PR, Fong JS: Interactions of dimethyl sulfoxide and non-steroidal anti-inflammatory agents in passive Heymann's nephritis. J Lab Clin Med 1986, 107: 425-430
61. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J Biol Chem 1994, 269:9889-9897
62. Lander HL, Tauras JM, Ogiste JS, Moss RA, Schmidt: Activation of the receptor for advanced glycation endproducts triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem 1997, 272:17810-17814
63. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 2001, 280:E685-E694